REG - Convatec Group PLC - Director/PDMR Shareholding

ConvaTecAnnouncement

08/08/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250808:nRSH4978Ua&default-theme=true

RNS Number : 4978U  Convatec Group PLC  08 August 2025

 8 August 2025

Convatec Group Plc

("Convatec" or "the Company")

 

Director/PDMR Shareholding

 

Sale of Ordinary Shares

 

The Company has been notified of the following transaction in relation to
Persons Discharging Managerial Responsibility ("PDMR") in respect of ordinary
shares of 10 pence each in the Company ("Shares").

 

On 7 August 2025, Karim Bitar sold 1,250,000 Shares. He continues to retain
the majority of his shareholding, as well as unvested PSP and LTIP shares.
Further information is set out in Convatec's Directors' Remuneration Report.

 

Karim Bitar said: "I have yesterday sold a minority of my shareholding in
Convatec. This follows the announcement about my medical leave of absence and
is for personal reasons unconnected with Convatec. I continue to retain a
substantial stake in Convatec and believe that the business is in very good
shape, with a clear strategy, strong leadership and attractive growth
prospects. I have full confidence in my Convatec colleagues and wish them
every success through this interim period."

 

The notification below, which has been made in accordance with the
requirements of the Market Abuse Regulation, provides further detail.

 

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Karim Bitar

 2    Reason for the notification

 a)   Position/status                                              Chief Executive Officer and PDMR

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Convatec Group Plc

 b)   LEI                                                          213800LS272L4FIDOH92

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary share of 10p each in Convatec Group Plc

      Identification code                                          GB00BD3VFW73

 b)   Nature of the transaction                                    Sale of Ordinary Shares

 c)   Price(s) and volume(s)

Price(s)  Volume(s)
                                                                   £2.265    1,250,000

 d)   Aggregated information

      - Aggregated volume                                          N/A - single transaction

      - Price                                                      £2.265

 e)   Date of the transaction                                      7 August 2025

 f)   Place of the transaction                                     London Stock Exchange

d)

 

Aggregated information

- Aggregated volume

N/A - single transaction

- Price

£2.265

e)

 

Date of the transaction

 

7 August 2025

f)

 

Place of the transaction

 

London Stock Exchange

 

Contacts

The person responsible for making this announcement is James Kerton, Company
Secretary, Convatec Group plc: cosec@convatec.com

 

Media: MediaRelations@convatec.com

 

Investor Relations: IR@convatec.com

 

Convatec Group Plc's LEI code is 213800LS272L4FIDOH92

 

Classification: 2.2 Information disclosed under article 19 of the Market Abuse
Regulation

 

About Convatec

Pioneering trusted medical solutions to improve the lives we touch: Convatec
is a global medical products and technologies company, focused on solutions
for the management of chronic conditions, with leading positions in Advanced
Wound Care, Ostomy Care, Continence Care, and Infusion Care. With more than
10,000 colleagues, we provide our products and services in around 90
countries, united by a promise to be forever caring. Our solutions provide a
range of benefits, from infection prevention and protection of at-risk skin,
to improved patient outcomes and reduced care costs. Convatec's revenues in
2024 were over $2 billion. The company is a constituent of the FTSE 100 Index
(LSE:CTEC). To learn more please visit http://www.convatecgroup.com
(http://www.convatecgroup.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFLFIDTTIDIIE